UNSPSC 51142549: Carbidopa anhydrous

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KR87B45RGH, chemically known as benzenepropanoic acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-, but more generally known as carbidopa anhydrous, which bears US NIH Compound Identifier 34359. European Medicines Agency schedules carbidopa anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06126MIG.

Most nations, for tariff purposes, schedule carbidopa anhydrous under HS 29280090. Carbidopa anhydrous bears US NLM identifiers UMLS ID C1881339 and NCI Concept Code C61803. SMILES: C[C@](CC1CCC(C(C1)O)O)(C(=O)O)NN.

UNSPSC 51142549 Carbidopa anhydrous is a Commodity code that nominally covers a single active pharmaceutical ingredient, but recent state and local opportunities show the code being applied to broader pharmaceutical procurement activity including naloxone, multi-source generic drugs, and over-the-counter products supplied through authorized wholesaler networks. State and local buyers soliciting under or near this code include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The work involves securing pharmaceutical products for health programs, emergency response systems, and employee health plans, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and supply products through dedicated distribution channels with specific pricing models and reporting obligations.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 drug deactivation systems annually for quarterly delivery to its Community Health Building, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer pharmacy initiative outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with questions due February 18, 2026, and proposals due March 26, 2026, with contract effectiveness July 1, 2026. The MMCAP procurement requires distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), submission of detailed NDC and packaging information, 3 percent administrative fee agreement, and insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability per occurrence.